PharmaCielo Ltd., a Canadian cannabis producer, plans to issue 11,145,999 common shares at $0.08 each to pay $891,681.85 in accrued interest on its 11% secured debentures. This share issuance is subject to approval by the TSX Venture Exchange and follows the terms of the debentures and exchange policies. The move helps PharmaCielo manage its debt obligations by converting interest payments into equity, potentially impacting shareholder structure. The company continues to focus on its ethical and sustainable cannabis cultivation and production in Colombia.
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Bragar Eagel & Squire, P.C. is investigating Starfighters Space, Inc. following the resignation of its founder and CEO Rick Svetkoff and company secretary Brenda Svetkoff due to disagreements with the board over company operations. The company disput...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
